<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Ethotoin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00754</strong>&#160; (APRD00962)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges. Ethotoin is no longer  commonly used.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00754/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00754/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00754.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00754.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00754.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00754.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00754.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00754">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Ethotoin</td><td>German</td><td>INN</td></tr><tr><td>Ethoto&#239;ne</td><td>French</td><td>INN</td></tr><tr><td>Ethotoinum</td><td>Latin</td><td>INN</td></tr><tr><td>Etotoina</td><td>Spanish</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Accenon</td><td>Dainippon Sumitomo</td></tr><tr><td>Peganone</td><td>Lundbeck</td></tr><tr><td>Pegoanone</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anticonvulsants">Anticonvulsants</a></li></ul></td></tr><tr><th>CAS number</th><td>86-35-1</td></tr><tr><th>Weight</th><td>Average: 204.2252<br>Monoisotopic: 204.089877638</td></tr><tr><th>Chemical Formula</th><td>C<sub>11</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub></td></tr><tr><th>InChI Key</th><td>SZQIFWWUIBRPBZ-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C11H12N2O2/c1-2-13-10(14)9(12-11(13)15)8-6-4-3-5-7-8/h3-7,9H,2H2,1H3,(H,12,15)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">3-ethyl-5-phenylimidazolidine-2,4-dione</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCN1C(=O)NC(C1=O)C1=CC=CC=C1</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB00754.gif?1265922772">show</a>(8.5 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Azolidines</td></tr><tr><th>Subclass</th><td>Imidazolidines</td></tr><tr><th>Direct parent</th><td>Phenylhydantoins</td></tr><tr><th>Alternative parents</th><td>Phenylimidazolidines; Ureides; N-substituted Carboxylic Acid Imides; Benzene and Substituted Derivatives; Tertiary Carboxylic Acid Amides; Tertiary Amines; Carboxylic Acids; Polyamines</td></tr><tr><th>Substituents</th><td>phenylimidazolidine; ureide; carboxylic acid imide, n-substituted; benzene; tertiary carboxylic acid amide; carboxamide group; tertiary amine; carboxylic acid derivative; carboxylic acid; polyamine; organonitrogen compound; amine</td></tr><tr><th>Classification description</th><td>This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the control of tonic-clonic (grand mal) and complex partial (psychomotor) seizures.</td></tr><tr><th>Pharmacodynamics</th><td>Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges.</td></tr><tr><th>Mechanism of action</th><td>The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges. Ethotoin inhibits nerve impulses in the motor cortex by lowering sodium ion influx, limiting tetanic stimulation.</td></tr><tr><th>Absorption</th><td>Fairly rapidly absorbed, however, the extent of oral absorption is not known.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic. The drug exhibits saturable metabolism with respect to the formation of N-deethyl and p-hydroxyl-ethotoin, the major metabolites.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Ethotoin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00979">p-Hydroxyl-ethotoin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1001">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>3 to 9 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Symptoms of overdose include drowsiness, loss of or impaired muscle coordination, nausea, visual disturbance, and, at very high doses, coma.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9936</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.5629</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.592</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8358</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9401</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8532</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7507</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9115</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.7383</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.914</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9619</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8591</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8483</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.7056
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8655
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.8423
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.1653 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.886
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8724
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Lundbeck inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.abbott.com">Abbott Laboratories Ltd.</a></li>
<li>Kaiser Foundation Hospital</li>
<li><a href="http://www.lundbeckinc.com">Lundbeck Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00404">Alprazolam</a></td><td>Ethotoin may increase the metabolism of alprazolam via CYP3A4.</td></tr><tr><td><a href="/drugs/DB01223">Aminophylline</a></td><td>Decreased effect of both products</td></tr><tr><td><a href="/drugs/DB01118">Amiodarone</a></td><td>Increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00673">Aprepitant</a></td><td>The CYP3A4 inducer, ethotoin, may decrease the effect of aprepitant.</td></tr><tr><td><a href="/drugs/DB00443">Betamethasone</a></td><td>The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, betamethasone.</td></tr><tr><td><a href="/drugs/DB01101">Capecitabine</a></td><td>Capecitabine increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00446">Chloramphenicol</a></td><td>Increases phenytoin, modifies chloramphenicol</td></tr><tr><td><a href="/drugs/DB00475">Chlordiazepoxide</a></td><td>Ethotoin may increase the metabolism of chlordiazepoxide via CYP3A4.</td></tr><tr><td><a href="/drugs/DB01114">Chlorphenamine</a></td><td>The antihistamine increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00501">Cimetidine</a></td><td>Increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00537">Ciprofloxacin</a></td><td>Decreases the hydantoin effect</td></tr><tr><td><a href="/drugs/DB00882">Clomifene</a></td><td>The enzyme inducer, ethotoin, decreases the effect of the hormone agent, clomifene.</td></tr><tr><td><a href="/drugs/DB00628">Clorazepate</a></td><td>Ethotoin may increase the metabolism of clorazepate via CYP3A4.</td></tr><tr><td><a href="/drugs/DB00363">Clozapine</a></td><td>Hydantoin decreases the effect of clozapine</td></tr><tr><td><a href="/drugs/DB00286">Conjugated Estrogens</a></td><td>The enzyme inducer, ethotoin, decreases the effect of the hormone agent, conjugated estrogens.</td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>The hydantoin decreases the effect of cyclosporine</td></tr><tr><td><a href="/drugs/DB01234">Dexamethasone</a></td><td>The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, dexamethasone.</td></tr><tr><td><a href="/drugs/DB00829">Diazepam</a></td><td>Ethotoin may increase the metabolism of diazepam via CYP3A4.</td></tr><tr><td><a href="/drugs/DB00255">Diethylstilbestrol</a></td><td>The enzyme inducer, ethotoin, decreases the effect of the hormone agent, diethylstilbestrol.</td></tr><tr><td><a href="/drugs/DB00280">Disopyramide</a></td><td>The hydantoin decreases the effect of disopyramide</td></tr><tr><td><a href="/drugs/DB00822">Disulfiram</a></td><td>Increases the effect of phenytoin</td></tr><tr><td><a href="/drugs/DB00254">Doxycycline</a></td><td>The anticonvulsant, ethotoin, decreases the effect of doxycycline.</td></tr><tr><td><a href="/drugs/DB00783">Estradiol</a></td><td>The enzyme inducer, ethotoin, decreases the effect of the hormone agent, estradiol.</td></tr><tr><td><a href="/drugs/DB00977">Ethinyl Estradiol</a></td><td>This product may cause a slight decrease of contraceptive effect</td></tr><tr><td><a href="/drugs/DB00949">Felbamate</a></td><td>Increased phenytoin levels and decreased felbamate levels</td></tr><tr><td><a href="/drugs/DB01023">Felodipine</a></td><td>The hydantoin decreases the effect of felodipine</td></tr><tr><td><a href="/drugs/DB00196">Fluconazole</a></td><td>Increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00687">Fludrocortisone</a></td><td>The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, fludrocortisone.</td></tr><tr><td><a href="/drugs/DB00544">Fluorouracil</a></td><td>Fluorouracil increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00472">Fluoxetine</a></td><td>Fluoxetine increases the effect of phenytoin</td></tr><tr><td><a href="/drugs/DB00690">Flurazepam</a></td><td>Ethotoin may increase the metabolism of flurazepam via CYP3A4.</td></tr><tr><td><a href="/drugs/DB00176">Fluvoxamine</a></td><td>Increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00158">Folic Acid</a></td><td>Folic acid decreases the levels of hydantoin</td></tr><tr><td><a href="/drugs/DB00695">Furosemide</a></td><td>The hydantoin decreases the effect of furosemide</td></tr><tr><td><a href="/drugs/DB00996">Gabapentin</a></td><td>Increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00317">Gefitinib</a></td><td>The CYP3A4 inducer, ethotoin, may decrease the serum concentration and therapeutic effects of gefitinib.</td></tr><tr><td><a href="/drugs/DB00741">Hydrocortisone</a></td><td>The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, hydrocortisone.</td></tr><tr><td><a href="/drugs/DB00619">Imatinib</a></td><td>The hydantoin decreases the levels of imatinib</td></tr><tr><td><a href="/drugs/DB00951">Isoniazid</a></td><td>Isoniazid increases the effect of phenytoin in 20% of patients</td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>Phenytoin decreases the effect of itraconazole</td></tr><tr><td><a href="/drugs/DB00555">Lamotrigine</a></td><td>Phenytoin may reduce levels of lamotrigine</td></tr><tr><td><a href="/drugs/DB00367">Levonorgestrel</a></td><td>Phenytoin decreases the contraceptive effect</td></tr><tr><td><a href="/drugs/DB00643">Mebendazole</a></td><td>The hydantoin decreases the efficiency of mebendazole</td></tr><tr><td><a href="/drugs/DB00603">Medroxyprogesterone Acetate</a></td><td>The enzyme inducer, ethotoin, decreases the effect of the hormone agent, medroxyprogesterone.</td></tr><tr><td><a href="/drugs/DB00351">Megestrol acetate</a></td><td>The enzyme inducer, ethotoin, decreases the effect of the hormone agent, megestrol.</td></tr><tr><td><a href="/drugs/DB00333">Methadone</a></td><td>The hydantoin decreases the effect of methadone</td></tr><tr><td><a href="/drugs/DB00563">Methotrexate</a></td><td>The antineoplasic agent decreases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00553">Methoxsalen</a></td><td>The hydantoin decreases the effect of psoralene</td></tr><tr><td><a href="/drugs/DB00379">Mexiletine</a></td><td>The hydantoin decreases the effect of mexiletine</td></tr><tr><td><a href="/drugs/DB00683">Midazolam</a></td><td>Ethotoin may increase the metabolism of midazolam via CYP3A4.</td></tr><tr><td><a href="/drugs/DB00370">Mirtazapine</a></td><td>The hydantoins may reduce mirtazapine plasma concentrations and pharmacological effects</td></tr><tr><td><a href="/drugs/DB00717">Norethindrone</a></td><td>This product may cause a slight decrease of contraceptive effect</td></tr><tr><td><a href="/drugs/DB00338">Omeprazole</a></td><td>Omeprazole increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00776">Oxcarbazepine</a></td><td>Oxcarbazepine increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB01303">Oxtriphylline</a></td><td>Decreased effect of both products</td></tr><tr><td><a href="/drugs/DB03585">Oxyphenbutazone</a></td><td>The NSAID, oxyphenbutazone, may increase the hydantoin effect of ethotoin.</td></tr><tr><td><a href="/drugs/DB00812">Phenylbutazone</a></td><td>The NSAID, phenylbutazone, may increase the hydantoin effect of ethotoin.</td></tr><tr><td><a href="/drugs/DB00860">Prednisolone</a></td><td>The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, prednisolone.</td></tr><tr><td><a href="/drugs/DB00635">Prednisone</a></td><td>The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, prednisone.</td></tr><tr><td><a href="/drugs/DB01224">Quetiapine</a></td><td>Phenytoin decreases the effect of quetiapine</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Rifampin decreases the effect of the hydantoin</td></tr><tr><td><a href="/drugs/DB00277">Theophylline</a></td><td>Decreased effect of both products</td></tr><tr><td><a href="/drugs/DB00208">Ticlopidine</a></td><td>Ticlopidine increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00620">Triamcinolone</a></td><td>The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, triamcinolone.</td></tr><tr><td><a href="/drugs/DB00897">Triazolam</a></td><td>Ethotoin may increase the metabolism of triazolam via CYP3A4.</td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>The CNS depressants, Triprolidine and Ethotoin, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>